The Comparation of Renal Anti‐Senescence Effects and Blood Metabolites between Dapagliflozin and Metformin in Non‐Diabetes Environment
Advanced Biology · 2023
DOI: 10.1002/adbi.202300199 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Advanced Biology, 2023. Verfasst von Lu Zeng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Nephrology and Blood Purification, the First Affiliated Hospital of Xi'an Jiaotong University, Shannxi, 710061, China. Hauptthemen laut MEDLINE: Metformin, Benzhydryl Compounds, Glucosides, Kidney. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Delaying kidney senescence process will benefit renal physiologic conditions, and prompt the kidney recovering from different pathological states. The renal anti‐senescence effects of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) and metformin have been proven in diabetic settings, but the roles of each one and combination of two drugs in natural kidney aging process remain undefined and deserve further research. Senescence‐accelerated mouse prone 8 (SAMP8) were orally administered dapagliflozin, metformin, and a combination of them for 16 weeks. Dapagliflozin exhibits better effects than metformin in lowering senescence related markers, and the combination therapy shows the best results. In vitro experiments demonstrate the same results that the combination of dapagliflozin and metformin can exert a better anti‐senescence effect. Blood metabolites detection in vivo shows dapagliflozin mainly leads to the change of blood metabolites enriched in choline metabolism, and metformin tends to induce change of blood metabolites enriched in purine metabolism. In conclusion, the results suggest dapagliflozin may have a better renal anti‐senescence effect than metformin in non‐diabetes environment, and the combination of the two drugs can strengthen the effect. The two drugs can lead to different blood metabolites alteration, which may lead to different systemic effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Critical Care Nephrology and Blood Purification, the First Affiliated Hospital of Xi'an Jiaotong University, Shannxi, 710061, China.
- Department of Obstetrics and Gynecology, the First Affiliated Hospital of Xi'an Jiaotong University, Shannxi, 710061, China.
- Department of Nephrology, Henan Provincial people's hospital, Henan, 450003, China.
- Department of Medical Examination, the First Affiliated Hospital of Xi'an Jiaotong University, Shannxi, 710061, China.
- Department of Nephrology, the First Affiliated Hospital of Xi'an Jiaotong University, Shannxi, 710061, China.
ORCID-Profile: Lu Zeng, Hongli Jiang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zeng, L., Chen, L., Gao, F., Li, J., Song, Y., Wei, L., Qu, N., Li, Y., & Jiang, H. (2023). The Comparation of Renal Anti‐Senescence Effects and Blood Metabolites between Dapagliflozin and Metformin in Non‐Diabetes Environment. Advanced Biology. https://doi.org/10.1002/adbi.202300199
Vancouver
Zeng L, Chen L, Gao F, Li J, Song Y, Wei L, et al. The Comparation of Renal Anti‐Senescence Effects and Blood Metabolites between Dapagliflozin and Metformin in Non‐Diabetes Environment. Advanced Biology. 2023. doi:10.1002/adbi.202300199
BibTeX
@article{Zeng2023,
author = {Zeng, Lu and Chen, Lei and Gao, Fanfan and Li, Jie and Song, Yangyang and Wei, Limin and Qu, Ning and Li, Yan and Jiang, Hongli},
title = {The Comparation of Renal Anti‐Senescence Effects and Blood Metabolites between Dapagliflozin and Metformin in Non‐Diabetes Environment},
journal = {Advanced Biology},
year = {2023},
doi = {10.1002/adbi.202300199}
}
EUVIMED